Wells Fargo lowered the firm’s price target on Elevance Health (ELV) to $391 from $424 and keeps an Overweight rating on the shares. The company established 2026 guide that the firm sees as being appropriately conservative, with opportunities for upside. Wells is lowering its 2027 / 2028 EPS to remove MA margin expansion and model Medicaid margins down 100bps pending given work requirements.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELV:
- Elevance Health price target lowered to $393 from $404 at Barclays
- Elevance Health price target lowered to $400 from $425 at UBS
- Elevance Health price target raised to $332 from $320 at Deutsche Bank
- Elevance Health price target lowered to $396 from $414 at Guggenheim
- Elevance Health Earnings Call Flags Reset Before Rebound